Analysts Anticipate Black Diamond Therapeutics (NASDAQ:REYN) Will Announce Earnings of $0.50 Per Share

Equities analysts expect that Black Diamond Therapeutics (NASDAQ:REYN) will report earnings per share of $0.50 for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Black Diamond Therapeutics’ earnings, with the lowest EPS estimate coming in at $0.49 and the highest estimate coming in at $0.51. The business is expected to announce its next quarterly earnings results on Thursday, August 6th.

According to Zacks, analysts expect that Black Diamond Therapeutics will report full year earnings of $1.88 per share for the current fiscal year, with EPS estimates ranging from $1.85 to $1.91. For the next year, analysts forecast that the business will post earnings of $1.91 per share, with EPS estimates ranging from $1.79 to $1.98. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow Black Diamond Therapeutics.

Black Diamond Therapeutics (NASDAQ:REYN) last issued its earnings results on Thursday, May 7th. The company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.27 by $0.03. The business had revenue of $691.00 million for the quarter, compared to analysts’ expectations of $695.40 million. The company’s revenue for the quarter was up 10.6% on a year-over-year basis.

REYN has been the topic of a number of research reports. Stifel Nicolaus raised their price target on Black Diamond Therapeutics from $38.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Citigroup raised their price target on Black Diamond Therapeutics from $33.00 to $41.00 and gave the stock a “buy” rating in a research note on Friday, May 15th. Zacks Investment Research upgraded Black Diamond Therapeutics from a “hold” rating to a “buy” rating and set a $38.00 price target on the stock in a research note on Friday, May 8th. Royal Bank of Canada restated a “hold” rating and issued a $31.00 price target on shares of Black Diamond Therapeutics in a research note on Monday, March 9th. Finally, Barclays restated a “hold” rating and issued a $34.00 price target on shares of Black Diamond Therapeutics in a research note on Sunday, May 10th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $36.60.

Shares of REYN stock traded up $0.59 on Friday, reaching $34.89. The stock had a trading volume of 332,481 shares, compared to its average volume of 851,251. The firm has a market cap of $7.32 billion and a PE ratio of 24.06. Black Diamond Therapeutics has a 1 year low of $21.61 and a 1 year high of $36.00. The stock’s 50 day simple moving average is $33.64.

Institutional investors have recently made changes to their positions in the stock. American International Group Inc. bought a new position in Black Diamond Therapeutics in the 1st quarter worth $26,000. Oppenheimer Asset Management Inc. bought a new stake in Black Diamond Therapeutics during the first quarter valued at about $29,000. Global Retirement Partners LLC bought a new stake in Black Diamond Therapeutics during the first quarter valued at about $41,000. Advisor Group Holdings Inc. bought a new stake in Black Diamond Therapeutics during the first quarter valued at about $41,000. Finally, Deutsche Bank AG bought a new stake in Black Diamond Therapeutics during the first quarter valued at about $67,000. 25.13% of the stock is currently owned by institutional investors.

About Black Diamond Therapeutics

Reynolds Consumer Products Inc, a consumer products company, produces and sells products across cooking, waste and storage, and tableware. It operates through four segments: Reynolds Cooking & Baking, Hefty Waste & Storage, Hefty Tableware, and Presto Products. The Reynolds Cooking & Baking segment produce foil, parchment paper, and disposable aluminum pans, as well as cooker liners.

See Also: Buyback

Get a free copy of the Zacks research report on Black Diamond Therapeutics (REYN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Black Diamond Therapeutics (NASDAQ:REYN)

Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.